UCLA Health
myUCLAhealth
School of Medicine
Toggle navigation
About Us
What is UCLA Health?
Contact Us
Your Feedback
Accountable Care Organization
Awards & Achievements
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
In the Community
340B Program
Industry Relations
Innovation
Leadership
News Releases
Price Transparency
Social Media
Contact
Your Feedback
Accountable Care Organization
Awards and Achievements
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
Industry Relations
Innovation
In the Community
340B Program
Leadership
News Releases
Price Transparency
Social Media
Subscribe to UCLA Health Newsletters
Conditions & Treatment
Health Library
Tests & Procedures
Drug Interaction Checker
Brain & Nervous System
Cancer
Children's Health
Heart Disease
Nutrition & Wellness
Pregnancy & Newborns
Orthopedics
Women's Health
Video Library
Cancer
Cardiovascular
Chiropractic
Cosmetic Surgery
Ear, Nose and Throat
Gastrointestinal
General Healthcare
Neurological
Obstetrics/Gynecology
See all videos...
Video Library
Locations
Hospitals
Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica
UCLA Mattel Children's Hospital
Resnick Neuropsychiatric Hospital
Institutes and Centers
Take a Virtual Tour
Medical Offices/Clinics
Primary Care
Specialty Care
Urgent Care Centers
Outpatient Surgery Centers
Community Cancer Care
Imaging/Radiology Locations
Clinical Labs
Pharmacies
Interactive Map
Locations Coming Soon
UCLA Hospitals
Take a Virtual Tour
Primary Care Practices
Specialty Care Practices
Urgent Care Centers
Outpatient Surgery Centers
Other Locations
Interactive Map
Coming Soon!
Medical Services
For Patients & Visitors
Directions & Parking
Appointments: Call, Click, Come In
Admissions Information
Preparing For Surgery
Patient Services
Security & Parking Services
Office of the Patient Experience
For International Patients
Lodging & Nearby Services
Around Westwood
Gift Shops & Flowers
Health Resources
Log in to myUCLAhealth
Billing and Insurance Information
Medical Records
Accountable Care Organization (ACO)
Price Transparency
Interactive Patient Education Videos (Emmi)
FAQs
Calendar of Events
Secure Email Messages
Share Your Story
Health Publications
Vital Signs Newsletters
Health Tips for Parents
Contact Us
Appointments: Call, Click, Come in
Admissions Information
Advance Directive
Directions & Parking
Patient Services
Medical Records
myUCLAhealth
Smoke-Free
Publications
Health Resources
Around Westwood
Lodging
Preparing For Surgery
Patient-focused Technology Council
Health Forms
End of Life Option Act: Resources & Materials
Frequently Asked Questions
Secure Email Messages
Gift Shops
For Healthcare Professionals
Referring a Patient
Continuing Medical Education
Ethics Center
UCLA HealthLink
Physician to Physician Access Line (P2P)
David Geffen School of Medicine at UCLA
Clinical Informatics Fellowship
Academic Positions
Physician Careers
UCLA School of Dentistry
UCLA School of Nursing
Department of Nursing
Physician Publications
Physicians Update
Clinical Updates
U Magazine
Physician to Physician Access Line (P2P)
Physician Careers
Clinical Informatics Fellowship
Flu Resources for Healthcare Professionals
Publications
Multimedia
UCLAMDCHAT Webinars
Community Health Program Videos
iTunes
Download Our Apps
Mini Med School
Demystifying Cancer Forum
TEDx UCLA Videos
Tips from our Physical Therapists
Patient Stories
Real Questions
Webinars on Demand
Pediatric Grand Rounds
Community Health Program Videos
UCLAMDChat Webinars
iTunes
Download Our Apps
Mini Med School
Demystifying Cancer Forum
TEDx UCLA Videos
Tips From Our Physical Therapists
Patient Stories
Real Questions
Back Pain Management
Find a Provider
UCLA Health
myUCLAhealth
School of Medicine
About Us
About Us
About Us
Contact
Your Feedback
Accountable Care Organization
ACO - Anthem Blue Cross PPO
Anthem Blue Cross PPO ACO FAQ
Awards and Achievements
UCLA Health hospitals again rank No. 1 in Los Angeles, No. 7 nationally
UCLA Designated a National Magnet Hospital
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
Industry Relations
Innovation
In the Community
Community Health
340B Program
Leadership
Dr. John Mazziotta
Johnese Spisso
Dr. Kelsey Martin
News Releases
Price Transparency
Social Media
Subscribe to UCLA Health Newsletters
About Us
Contact
Your Feedback
Accountable Care Organization
Awards and Achievements
Careers
Careers for Physicians
Departments - Administrative
Departments - Clinical
Giving to UCLA Health
Industry Relations
Innovation
In the Community
340B Program
Leadership
News Releases
Price Transparency
Social Media
Subscribe to UCLA Health Newsletters
Home
About Us
News Releases
News Releases
Share this
Health and Behavior
Legal expert explores risks, rewards of using stem cell products
04/11/2012
The brave new world of stem cell research dangles the exciting potential for a host of leading-edge treatments that may one day help cure debilitating diseases such as Alzheimer's, Parkinson's and other maladies that today cannot be treated with modern medicine.
However, not much thought has been given to how those products might be regulated and how issues of legal liability may be addressed in a way that encourages scientific innovation but also protects the patients for whom these treatments might provide great relief.
Now, an attorney and law professor from the UCLA School of Law and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA has developed a roadmap that could help guide researchers, stem-cell product manufacturers, physicians and patients through the complex maze of imagining, creating and developing stem cell products and using them to treat disease.
"Stem cell research and its eventual applications hold enormous promise, but they also carry some significant risks," said distinguished professor of law Stephen R. Munzer, whose new article appears April 11 in the Boston University
Journal of Science and Technology Law
. "Our understanding of the number and gravity of those risks right now is incomplete and uncertain. Developing a plan now that details how to deal with such issues as stem-cell product liability is important because we need to think carefully and rationally about how to address these issues before the market is flooded with products."
In the article, Munzer offers suggestions on how stem cell products might be classified in the future; examines how applying existing product liability rules to stem cell products is inadequate; details the economic considerations for a stem-cell liability regime; and offers his views of what the law should be on liability for stem cells.
"One thing I detect from the stem cell scientists I've spoken to is a certain amount of judicious caution," he said. "What they don't want is to have people rushing to get something approved by the FDA and then see it result in unanticipated, unforeseeable problems."
One of the byproducts of that judicious caution, both of the risk of liability and the potential risk to patients, Munzer said, has been that scientists and biotechnology companies are initially going after the so-called low-hanging fruit of stem cell treatments — those projects that appear to have the least amount of risk and the maximum benefit, such as treatments for retinal disease as opposed to organ regeneration.
In the article, Munzer also emphasizes the "ethics of risk," or having all those involved from the conception of an idea for a stem cell product to its eventual development, manufacture and administration, accountable for the risks they may be imposing on patients.
"The scientists who come up with the ideas for these products, the people who design them, the biotech companies that manufacture them and produce them in large numbers, and the treating physicians who ultimately will be administering these treatments all have to be accountable, as well as the FDA, which is charged with regulating them," Munzer said.
Munzer likened the anticipation for potential stem cell products to the excitement created in the 1980s and 1990s over early gene therapies and what may have been a rush to test the therapies without adequately considering the risks. That potential for new gene therapy treatments was temporarily derailed after Jesse Gelsinger, an 18-year-old, died in 1999 as a result of treatment in a gene therapy trial.
"Existing blood products, growth factors, vaccines — we've got more understanding of how those things work, and that is not true in the case of stem cells," Munzer said. "We want to create a strict liability regime that encourages innovation but on the other hand does not encourage it so much that products are put on the market long before they should be."
Munzer suggests creating a social-insurance arrangement that would pool resources from everyone involved, from the scientists to the manufacturers to the treating physician and the patients, contributing to a fund that could eventually be used to compensate those harmed by stem cell products during their testing. His proposal is similar to the
National Vaccine Injury Compensation Program
, created in 1988 as a no-fault alternative to the traditional tort system created to ensure an adequate supply of vaccines, stabilize vaccine costs, and establish and maintain an accessible and efficient forum for individuals found to be injured by certain vaccines.
Munzer also recommends limiting punitive damages in stem cells cases, but only if the product has been approved by the U.S. Food and Drug Administration, the FDA regulatory requirements have been strictly followed, the risks of the products have become more understood and predictable, and the FDA has gained sufficient experience in regulating the products.
Munzer's liability roadmap could be of value to courts, lawyers and regulatory bodies in navigating what is to come in stem cell product development. It also should be considered a dynamic document, he said, that responds to what is learned in the coming decades about the creation and development of stem cell products.
"It is important to address these issues this early with as much insight as we can bring to it, recognizing that there will be, as the years go on, more information and a better understanding of what we're doing," he said. "Starting to address this now instead of waiting five to 10 years is vital, as it will be much easier to prevent potential mishaps and messes from occurring than it will be to try to clean them up later."
Munzer's article attempts to tackle problems that are on or just beyond the horizon, and looks to what has happened in the past for guidance.
"The product liability claims regarding stem cell products will require the most exacting attention to their safety and effectiveness that is possible without imposing an undue burden on manufacturers," the study states. "No existing category offers a perfect legal model for stem cell products. However, we can tease out pertinent features of these categories for tort litigation to show what might work well for stem cell products. Definitive recommendations must wait for these products to appear on the market and for their risks and rewards to become better understood over the coming decades."
The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
:
UCLA's stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Broad Stem Cell Research Center is committed to a multidisciplinary, integrated collaboration among scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed toward future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine at UCLA, UCLA's Jonsson Cancer Center, the UCLA Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science.
For more news, visit the
UCLA Newsroom
and follow us on
Twitter
.
Media Contact:
Kim Irwin
(310) 794-2262
kirwin@mednet.ucla.edu
Media Contact
Kim Irwin
(310) 794-2262
kirwin@mednet.ucla.edu
Latest News
Health and Behavior
Low-income undocumented adults are largely locked out of health care in California, study finds
02/19/2019
Nine in 10 lack insurance.
Health and Behavior
UCLA faculty voice: Adolescents have a fundamental need to contribute
02/19/2019
No longer children but not yet adults, adolescents need opportunities to learn and prepare for their entrance into the broader society.
Health and Behavior
Sexually transmitted infections are on the rise. Here’s what you need to know to protect yourself
02/14/2019
In a Q&A, UCLA’s Dr. Leena Nathan explains which infections sexually active people are more likely to be exposed to and to contract.
Health and Behavior
Electrical activity early in fruit flies’ brain development could shed light on how neurons wire the brain
02/12/2019
A study by UCLA neuroscientists suggests that the signals could help neurons find each other to form networks.
Health and Behavior
For recurrent glioblastoma, immunotherapy before surgery appears to help more than afterward
02/11/2019
“We now have a rational and logical way to develop immunotherapies going forward and a clinical development process for doing it,” said UCLA's Dr. Timothy Cloughesy.
Like Us on Facebook
Follow Us on Twitter
Subscribe to Our Videos on YouTube
Follow us on Instagram
Connect with Us on LinkedIn
Follow us on Pinterest
Follow us on Flickr
Follow us on Sharecare
×
Sign in to myUCLAhealth